Xi Yang, PhD, DABT, is a board-certified toxicologist and senior research scientist at RTI focused on global public health. She designs, contracts, and monitors nonclinical programs that support drug development, with a current focus on HIV and tuberculosis. She has over 10 years of toxicology research and regulatory experience, with expertise in evaluating nonclinical data submitted to Investigational New Drug Applications and New Drug Applications in cardiology and nephrology. Dr. Yang also offers regulatory recommendations of nonclinical strategies to support clinical trials from First-In-Human through post-marketing.
Before joining RTI in 2022, Dr. Yang worked at the FDA as a nonclinical reviewer evaluating the results of in-silico, in-vitro, ex-vitro, and in-vivo toxicology studies. She also led a multidisciplinary research team investigating the safety of FDA-regulated products, including drugs, tobacco, and natural products.
